Cagrilintide: Long-Acting Amylin Analog Research Overview

Reference values identify the molecule. Salt forms such as the acetate have a different formula and molecular weight, so always confirm identity and purity against the batch Certificate of Analysis.

Cagrilintide is a synthetic peptide modeled on amylin, a 37-residue hormone co-secreted with insulin by pancreatic beta cells. Native human amylin is a hard laboratory molecule. It is short-lived in experimental systems, and it readily aggregates into amyloid fibrils in solution. Cagrilintide was engineered to keep amylin-family receptor activity while solving both problems.

Its design, described by Novo Nordisk scientists (Kruse et al., Journal of Medicinal Chemistry, 2021), combines:

• Sequence changes (including proline substitutions, as in the earlier analog pramlintide) that reduce the tendency to form fibrils
• A disulfide bridge between the two cysteines near the N-terminus, as in native amylin
• A C-terminal amide, as in native amylin
• Lipidation: a C20 fatty diacid (eicosanedioic acid) attached through a γ-glutamic acid linker to the N-terminal lysine

The fatty diacid lets the peptide bind reversibly to serum albumin, which slows its clearance. This is the same general strategy used in long-acting GLP-1 analogs such as semaglutide.

There is no single gene for an amylin receptor. Amylin receptors are complexes of the calcitonin receptor (CTR), a class B1 G protein-coupled receptor, with one of three receptor activity-modifying proteins (RAMPs):

• AMY1 = CTR + RAMP1
• AMY2 = CTR + RAMP2
• AMY3 = CTR + RAMP3

CTR on its own responds best to calcitonin. Paired with a RAMP, it gains high affinity for amylin. Cagrilintide activates both: the AMY1–3 complexes and CTR alone. That is why it is described as a non-selective amylin and calcitonin receptor agonist, and why it is sometimes grouped with “dual amylin and calcitonin receptor agonists” (DACRAs) in the research literature.

All of these receptors couple mainly to G_s, raising intracellular cAMP. They can also recruit β-arrestins and activate ERK1/2. The same RAMPs pair with the calcitonin receptor-like receptor (CLR) to form CGRP and adrenomedullin receptors, so amylin analogs are often profiled against those receptors too.

In vitro, cagrilintide is used as a reference tool for amylin and calcitonin receptor pharmacology. Common approaches include:

• cAMP accumulation assays (HTRF, luminescence or reporter-gene formats) in cells expressing CTR alone or CTR with RAMP1, RAMP2 or RAMP3
• Selectivity panels that compare potency (EC₅₀) and maximal response (E_max) across AMY1–3, CTR, and the CGRP and adrenomedullin receptors
• β-arrestin recruitment and receptor internalization assays to profile signaling bias
• Fibrillation and stability studies, such as thioflavin T fluorescence, comparing cagrilintide with native amylin and pramlintide
• Albumin-binding studies that examine how the fatty diacid changes free-peptide concentration in assay media

Because cagrilintide binds albumin, the amount of serum or albumin in the assay buffer can shift its apparent potency. Report media composition alongside any EC₅₀ value.

The key research contrast is selectivity. Cagrilintide activates CTR alone about as well as the amylin receptors, while eloralintide was engineered to favor AMY1. Running both across the same CTR and AMY1–3 cell lines is a direct way to study what each receptor contributes. See the Eloralintide research overview for more on that molecule.

No. Cagrilintide does not act on the GLP-1 receptor. It is often mentioned alongside GLP-1 compounds for two reasons. Novo Nordisk has studied it together with semaglutide, a GLP-1 receptor agonist, in a fixed combination known as CagriSema. And many suppliers shelve amylin analogs in the same “GLP” or metabolic collection as incretin peptides.

The two receptor systems are separate. GLP-1, GIP and glucagon receptors are class B1 GPCRs that work without a RAMP partner. Amylin receptors need CTR plus a RAMP. For the incretin side, see the tirzepatide research overview and the retatrutide research overview.

Cagrilintide is an investigational molecule and is not an authorized product for any use. Novo Nordisk has studied it on its own and in the CagriSema combination with semaglutide. The combination has completed Phase 3 studies in the REDEFINE program and has been submitted for regulatory review in the United States.

For current study designs, search ClinicalTrials.gov for cagrilintide. For peer-reviewed literature, see PubMed. Clinical findings are reported by the developer and should be read in the original sources. This page doesn’t summarize them.

Research-grade cagrilintide is supplied as a lyophilized peptide. A complete Certificate of Analysis should include:

• Identity by mass spectrometry (ESI-MS or MALDI-TOF): the observed mass compared with the expected molecular weight for the stated salt form
• Purity by reversed-phase HPLC with UV detection, reported as percent area of the main peak. Lipidated peptides are strongly retained, so the method should be suited to them
• Lot number and test date, so every result traces to the vial in hand
• Endotoxin results (LAL) where material is intended for cell-based assays
• Appearance and net peptide content, which matter for preparing accurate stock concentrations

Learn how to read one in our guide to the peptide certificate of analysis, and see HPLC testing for peptides and endotoxin testing. NuRev publishes batch certificates in its COA library.

Lipidated amylin analogs are prone to adsorption and, at high concentrations, self-association. General practice for lyophilized peptides applies:

• Store the sealed vial at −20 °C, protected from light and moisture. Short-term storage at 2–8 °C is acceptable.
• Let the vial reach room temperature before opening to limit condensation.
• Dissolve in a solvent suited to the assay, mix gently rather than vortexing hard, and divide solutions into single-use aliquots.
• Avoid repeated freezing and thawing, and use low-binding tubes and tips at low concentrations.

More detail is in peptide storage best practices and preparing lyophilized peptide solutions for laboratory assays.

NuRev supplies research peptides for laboratory and in-vitro research use only. They are not for human or veterinary use.